Cultivated meat startup Omeat has completed the first commercial sale of Plenty, an ethical and affordable alternative to fetal bovine serum (FBS). Plenty is available through the newly launched B2B arm of Omeat for cultivated meat companies in the US.

Plenty is derived from regenerative plasma from cows on Omeat's carbon-negative farm, offering a slaughter-free growth medium. Omeat claims its process is more efficient and can yield 20x more meat per cow than traditional slaughter methods.

Unlike cultivated meat, Plenty does not require FDA or USDA approval, allowing the company to begin revenue generation. According to the company, Plenty has potential applications beyond cultivated meat, such as regenerative medicine and vaccine production.

Analyst QuickTake: Having recently emerged from stealth , Omeat is on track to become one of the quickest cell-cultured companies to begin revenue generation. While only available in the US, recent developments in the cell-cultured space in the EU, such as the Netherlands greenlighting cultivated meat tastings and Aleph Farms’ submission for approval in the UK and Switzerland , could potentially open up new markets for Omeat.